• Measuring Drug Response Beyond Cell Viability

  2026-09-28

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why growth inhibition and cell killing should not be treated as interchangeable readouts. Its framework helps researchers design better in vitro drug-response experiments and interpret timing, endpoint selection, and cytotoxicity data more cautiously.

• Lambda Protein Phosphatase in BMAL1 Studies

  2026-09-28

  Use Lambda Protein Phosphatase to distinguish phosphorylation-dependent BMAL1 behavior from changes in protein abundance or antibody performance. This workflow pairs controlled dephosphorylation with immunoblotting and condensate assays, while accounting for the enzyme’s Mn²⁺ requirement and common inhibitor-related failure points.

• Sodium Ascorbate: Separating ROS and Immune Signals

  2026-09-27

  Sodium Ascorbate is a mineral salt of ascorbic acid used to investigate oxidative tumor-cell injury. This article distinguishes its ROS-focused evidence from a separate GPNMB immunotherapy study and shows how that distinction can sharpen assay design.

• Penicillin G Sodium: Practical Research Workflows

  2026-09-26

  Build reproducible susceptibility and exposure studies with a natural penicillin antibiotic, while accounting for active growth, strain-level resistance, and solution stability. This guide turns Penicillin G Sodium product characteristics into practical assay choices and separates infection-research evidence from an unrelated cancer-mechanism study.

• Streptavidin – FITC for Reliable Cell Assays

  2026-09-26

  Learn how Streptavidin – FITC (SKU K1081) can detect biotinylated markers in cell-based workflows without being mistaken for a direct viability readout. Practical guidance covers fluorescence controls, assay optimization, interpretation, and product selection.

• Mitomycin C in Translational Oncology: Beyond Cytotoxicity

  2026-09-25

  Mitomycin C offers a defined DNA-damage perturbation for cancer research, while emerging tumor-vaccine work highlights a distinct immune route to tumor control. This article shows how to use both lines of evidence to build more discriminating translational studies—without implying an untested combination.

• Prednisolone Workflows for GR and ERAD Research

  2026-09-25

  Use Prednisolone to build controlled glucocorticoid receptor and inflammation assays, while keeping ERAD-degrader experiments mechanistically distinct. A practical workflow connects these research areas without mistaking Prednisolone for the desonide-based ERADEC warhead reported in the reference study.

• N-MYC–eIF4G1 Axis Sustains inv(16) AML Survival

  2026-09-24

  This study identifies N-MYC as a survival regulator in inv(16) acute myeloid leukemia (AML) and connects it to eIF4G1, a previously unreported leukemic target. Its findings link a MYCN enhancer to N-MYC expression and support further investigation of the N-MYC/eIF4G1 axis, while leaving its therapeutic relevance beyond preclinical models to be tested.

• Metal–Chlorogenic Acid Assemblies Suppress Inflammation

  2026-09-24

  Zhang et al. report that assembling chlorogenic acids with iron or copper produces supramolecular complexes with stronger anti-inflammatory effects than the parent compounds in LPS-stimulated RAW264.7 macrophages. The findings connect reduced inflammatory mediator production with inhibition of NF-κB signaling and lower iNOS and COX-2 expression, while leaving questions about direct molecular targets and in vivo relevance for future work.

• Diclofenac in Human Intestinal Organoid Research

  2026-09-23

  Use Diclofenac as a defined non-selective COX inhibitor to connect cyclooxygenase inhibition assay results with human-relevant intestinal exposure and metabolism studies. This workflow combines mechanistic inflammation readouts with hiPSC-derived organoid and monolayer models, while addressing solubility, vehicle, differentiation, and reproducibility risks.

• Separating Growth Arrest from Cell Death in Cancer

  2026-09-22

  Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its framework encourages researchers to distinguish proliferative arrest from cell killing and to account for their different proportions and timing when designing in vitro studies.

• Nebivolol Hydrochloride in Assay Design

  2026-09-22

  Nebivolol hydrochloride is more than a selective β1-adrenoceptor antagonist: it can serve as a mechanistic boundary condition in cardiovascular and mTOR-related assay design. This article translates recent drug-sensitized yeast findings into practical decisions for pathway attribution, controls, and reproducible research.

• Drug Response Measurement in Cancer In Vitro

  2026-09-21

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but noninterchangeable drug-response dimensions. The framework has practical implications for interpreting dose–response experiments, separating cytostatic from cytotoxic effects, and designing time-resolved cancer research workflows.

• Streptavidin-FITC: From Binding to Trafficking

  2026-09-21

  Streptavidin-FITC converts biotin labeling into a sensitive, spatially interpretable fluorescence readout. This article explains how to design and interpret biotin-streptavidin assays across nanoparticle trafficking, microscopy, and flow cytometry without confusing uptake with functional delivery.

• Live-Dead Cell Staining Kit: Practical Workflows

  2026-09-20

  Learn how dual-dye viability imaging can strengthen corneal epithelial stress models, flow cytometry, and drug cytotoxicity testing. This workflow-focused guide explains assay design, quantitative readouts, troubleshooting, and how to pair membrane-integrity data with ferroptosis and inflammation measurements.

8690 records 1/580 page Next 12345 下5页 Last page